PROCEPT BioRobotics (PRCT) to Release Earnings on Wednesday

Key Points

• PROCEPT BioRobotics is set to release its Q2 2025 earnings data on August 6th, with analysts forecasting a loss of ($0.41) per share and a revenue of $75.67 million.
• The company's stock is currently valued at $53.73, having a market cap of $2.97 billion and a P/E ratio of -31.61.
• Insider trading activity shows significant selling, with a director recently selling 25,000 shares valued at over $1.5 million, resulting in a 63.51% decrease in their ownership.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) is projected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.41) per share and revenue of $75.67 million for the quarter.

PROCEPT BioRobotics Trading Up 0.6%

PRCT traded up $0.28 during midday trading on Friday, reaching $48.79. 140,752 shares of the company's stock traded hands, compared to its average volume of 969,639. The firm has a fifty day moving average of $58.65 and a two-hundred day moving average of $60.45. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -28.80 and a beta of 1.07. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75. PROCEPT BioRobotics has a 52 week low of $47.04 and a 52 week high of $103.81.

Wall Street Analyst Weigh In

PRCT has been the topic of a number of research analyst reports. Morgan Stanley reduced their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. Bank of America reduced their target price on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Friday, April 25th. Stephens initiated coverage on PROCEPT BioRobotics in a report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 target price on the stock. Wall Street Zen downgraded PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a report on Saturday, July 12th. Finally, Truist Financial reduced their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $84.13.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total value of $1,537,250.00. Following the sale, the director owned 14,363 shares in the company, valued at $883,180.87. This represents a 63.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 100,000 shares of company stock valued at $6,271,250. Corporate insiders own 6.60% of the company's stock.

Institutional Trading of PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently made changes to their positions in PRCT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of PROCEPT BioRobotics by 9.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company's stock worth $8,923,000 after buying an additional 13,767 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of PROCEPT BioRobotics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company's stock worth $1,654,000 after buying an additional 10,002 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company's stock worth $1,101,000 after buying an additional 1,286 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).